Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31070870 | 0.98 | L3MBTL1 (0.68) | RAB9ANPC1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL29818202 | 0.95 | L3MBTL1 (0.63) | RAB9ANPC1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL29818035 | 0.92 | KMT2A (0.65) | RAB9ANPC1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL3212175 | 0.92 | KMT2A (0.65) | RAB9ANPC1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL6707186 | 0.89 | RAB9A (0.79) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL9265040 | 0.89 | RAB9A (0.79) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL3822970 | 0.88 | KMT2A (0.64) | RAB9ANPC1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL20288109 | 0.85 | KDM1A (0.62) | RAB9ANPC1L3MBTL1KMT2AMEN1 | |
| SCHEMBL19445791 | 0.84 | RAB9A (0.72) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL26413302 | 0.83 | RAB9A (0.70) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398139-B2 | Modulators of AMPA receptor signaling | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2025-08-26 | — | — | US | disclosed |
| EP-3935059-B1 | MODULATORS OF AMPA RECEPTOR SIGNALING | CAMH (CA) | 2025-04-23 | — | — | EP | disclosed |
| CN-113891891-B | Modulators of AMPA receptor signaling | 戒毒及精神健康中心 | 2024-10-11 | — | — | CN | disclosed |
| CN-113999131-B | Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light | 苏州大学 | 2022-06-28 | — | — | CN | disclosed |
| US-20220185813-A1 | MODULATORS OF AMPA RECEPTOR SIGNALING | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2022-06-16 | — | — | US | disclosed |
| CN-113999131-A | Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light | 苏州大学 | 2022-02-01 | — | — | CN | disclosed |
| CN-113891891-A | Modulators of AMPA receptor signaling | 戒毒及精神健康中心 | 2022-01-04 | — | — | CN | disclosed |
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-8431709-B2 | Acylation reaction of hydroxyl group | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | RAB9A 1274/4885NPC1 274/4885L3MBTL1 3663/4885 |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | RAB9A 1274/4885NPC1 274/4885L3MBTL1 3663/4885 |
| US-20220185813-A1 | MODULATORS OF AMPA RECEPTOR SIGNALING | GRM2, GRM1, GRIK2 | RAB9A 3280/4885NPC1 2862/4885L3MBTL1 3333/4885 |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | ADH5, ADH1A, ACADM | RAB9A 3717/4885NPC1 2077/4885L3MBTL1 3601/4885 |
| US-12398139-B2 | Modulators of AMPA receptor signaling | GRM2, GRM1, GRIK1 | RAB9A 3195/4885NPC1 2570/4885L3MBTL1 3511/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | RAB9A 1274/4885NPC1 274/4885L3MBTL1 3663/4885 |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, CLN6, AADAT | RAB9A 1274/4885NPC1 274/4885L3MBTL1 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.